LIMK2 and triple-negative breast carcinoma: LIMK2 is overexpressed in triple-negative breast cancer (TNBC) and pharmacological inhibition, with LX7101 or TH-257, leads to the inhibition of the metastatic characteristics of TNBC cells (migration, invasion, actomyosin contractility, and extracellular matrix degradation).